Penumbra AI Stock Analysis
Want to see PEN full AI Analyst Report?
Penumbra (PEN) AI Stock Analysis
Penumbra
(NYSE:PEN)
The score is primarily supported by strong financial performance—rapid revenue growth into TTM, solid profitability, healthy cash generation, and low leverage. The rating is held back by expensive valuation (high P/E) and mixed technical positioning, including trading below the 200-day moving average.
Penumbra (PEN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $12.65B
- Dividend Yield
- ―
- Average Volume (3M)
- 355.03K
- Price to Earnings (P/E)
- 80.4
- Beta (1Y)
- 0.03
- Revenue Growth
- 16.98%
- EPS Growth
- -5.62%
- Country
- US
- Employees
- 4,700
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Penumbra Business Overview & Revenue Model
Company Description
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...
How the Company Makes Money
Penumbra makes money primarily by selling medical devices and single-use consumables used in interventional procedures. The company’s revenue model is largely product-driven: hospitals and healthcare providers purchase Penumbra’s thrombectomy and int...
Penumbra Earnings Call Summary
The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During Penumbra's third-quarter 2025 conference call, the company reported total revenue of $354.7 million, marking a 17.8% year-over-year growth on a reported basis and 16.9% in constant currency. U.S. revenue reached $275 million, a 21.5% increase compared to the previous year. Specifically, U.S. thrombectomy sales rose by 18.5% to $192 million, while the VTE franchise led corporate growth with a 34% rise. Meanwhile, U.S. embolization and access revenue soared by 29.2% to $83 million. International revenue was $79.7 million, reflecting a 6.6% year-over-year increase. The company's gross margin expanded by 130 basis points to 67.8%, and operating income stood at $48.8 million, or 13.8% of revenue. Penumbra's guidance for the year was raised to $1.375 billion to $1.380 billion in revenue, with anticipated U.S. thrombectomy growth of 20% to 21% for 2025. The company remains focused on expanding its market presence, particularly through innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.
Penumbra Financial Statement Overview
Summary
Strong revenue acceleration into TTM alongside robust gross margin (~68%) and improved profitability (TTM operating margin ~9.8%, net margin ~10.1%). Balance sheet is conservatively levered (TTM debt-to-equity ~0.13) with growing equity, and cash conversion is solid (operating cash flow ~1.19x net income). Key offsets are margin compression versus 2025 and a recent decline in free cash flow (TTM FCF down ~7.2% YoY).
Income Statement
78PositiveBalance Sheet
86Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56B | 1.40B | 1.19B | 1.06B | 847.13M | 747.59M |
| Gross Profit | 1.06B | 942.44M | 755.00M | 682.64M | 535.21M | 475.38M |
| EBITDA | 229.21M | 223.91M | 45.99M | 108.65M | 29.96M | 7.84M |
| Net Income | 157.02M | 177.69M | 14.01M | 90.95M | -2.00M | 5.28M |
Balance Sheet | ||||||
| Total Assets | 2.03B | 1.83B | 1.53B | 1.56B | 1.37B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 673.61M | 544.82M | 340.13M | 289.19M | 188.03M | 254.88M |
| Total Debt | 209.39M | 219.70M | 223.39M | 234.34M | 235.77M | 173.55M |
| Total Liabilities | 441.59M | 398.92M | 382.25M | 377.36M | 372.03M | 290.32M |
| Stockholders Equity | 1.58B | 1.43B | 1.15B | 1.18B | 998.86M | 953.93M |
Cash Flow | ||||||
| Free Cash Flow | 200.29M | 174.93M | 147.30M | 82.12M | -74.96M | -11.68M |
| Operating Cash Flow | 261.05M | 238.66M | 168.48M | 97.33M | -55.66M | 9.50M |
| Investing Cash Flow | -338.69M | -404.59M | 77.62M | -16.08M | 54.79M | -21.73M |
| Financing Cash Flow | 11.12M | 26.53M | -87.01M | 16.20M | 11.62M | 836.00K |
Penumbra Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PEN, the sentiment is Negative. The current price of 320.91 is below the 20-day moving average (MA) of 321.95, above the 50-day MA of 320.15, and below the 200-day MA of 325.71, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 40.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PEN.
Penumbra Risk Analysis
Penumbra disclosed 64 risk factors in its most recent earnings report. Penumbra reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPenumbra Peers Comparison
Overall Rating
MDT81Outperform
SYK75Outperform
ABT67Neutral
PHG67Neutral
PEN67Neutral
BSX64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $131.58B | 25.15 | 10.60% | 2.78% | 9.77% | 12.28% | |
| 75Outperform | $117.88B | 32.77 | 15.61% | 1.14% | 7.87% | 22.82% | |
| 67Neutral | $187.95B | 40.19 | 9.11% | 2.32% | 10.00% | -66.06% | |
| 67Neutral | $29.39B | 27.22 | 8.44% | 3.26% | ― | ― | |
| 67Neutral | $12.65B | 80.43 | 10.44% | ― | 16.98% | -5.62% | |
| 64Neutral | $64.27B | 18.71 | 13.87% | ― | 8.88% | 25.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PEN | Penumbra Inc. | 320.91 | 42.40 | 15.22% | |
| ABT | Abbott Laboratories | 108.52 | -18.36 | -14.47% | |
| BSX | Boston Scientific | 44.34 | -57.42 | -56.43% | |
| PHG | Koninklijke Philips N.V. | 30.34 | 3.25 | 12.01% | |
| MDT | Medtronic | 102.86 | 9.67 | 10.38% | |
| SYK | Stryker Corp | 309.64 | -46.54 | -13.07% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
